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To my father whose struggle with high cholesterol inspired me to search for treatments
for atherosclerosis
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ABSTRACT
Atherosclerosis is a cardiovascular disease that is characterized by the hardening of
arteries through the formation of cholesterol plaques. Cyclodextrins have the potential to
treat atherosclerosis by shrinking plaques. These cyclic oligosaccharides are known to
make complexes with cholesterol and have potentially dangerous side effects such as
cytotoxicity and gut microbiome changes. This study looked for potential negative effects
of cyclodextrins and cholesterol on gut bacteria. It was hypothesized that Bacteroides
vulgatus will have decreased growth when grown in broth with cholesterol. In contrast, it
was hypothesized that Clostridium bolteae will have decreased growth when grown in
broth with cyclodextrins. Due to the fact that these bacteria are anaerobic, Clostridium
bolteae and Bacteroides vulgatus, were grown using Gifu Anaerobic Broth under CO2.
Data was collected by using a spectrophotometer to measure changes in bacterial growth
throughout the growth cycle. Each bacteria was treated with one of three chemicals at one
of three concentrations to make a total of 9 different conditions. α-cyclodextrin, 2hydroxypropyl-β-cyclodextrin, and cholesterol were used to treat the bacteria at
concentrations of 1 mM, 10 mM, and 100 mM. The slopes of the log phase of bacterial
growth were compared using a two tailed t-test with α=0.05. Growth of Clostridium bolteae
was significantly inhibited for most of the cyclodextrin treatments and all the cholesterol
concentrations. Bacteroides vulgatus growth was inhibited by 100 mM concentrations of
cholesterol and α-cyclodextrins. Interestingly, Bacteroides vulgatus growth was
significantly increased when grown with 1 mM and 10 mM concentrations of cholesterol.
These results demonstrate that cyclodextrins are associated with inhibited growth for these
two prototypic gram negative and gram positive gut bacteria. Moreover, expansion of this
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study to other gut bacteria is key for a deeper understanding of the impact that cyclodextrins
would have on the gut microbiome as a whole.
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INTRODUCTION
Atherosclerosis is a cardiovascular disease that has one of the highest mortality
rates in the world. It is characterized by the formation of cholesterol-filled plaques that
are chronically inflamed and continue to develop until they occlude the artery or break
off causing a stroke or heart attack. Statins are the current standard treatment for
atherosclerosis and for the precursor to atherosclerosis, high cholesterol. These drugs
lower the levels of unhealthy lipoproteins to slow the progression of plaques (Lusis
2000). However, there remains a gap in medical treatment for a way to reduce
inflammation and remove cholesterol from plaques to lower the risk for heart attacks and
strokes. Cyclodextrins are oligosaccharides that have been found to regress
atherosclerosis through the potential mechanism of decreasing inflammation and
shrinking plaques by extracting cholesterol from membranes (Zimmer et al. 2016). Using
a computer simulation, it was demonstrated that the mechanism for this removal may be
that cyclodextrins form dimers to pull out cholesterol molecules, forming 2:1
cyclodextrin-cholesterol complexes (LóPez et al. 2011).
The most widely studied cyclodextrin, 2-Hydroxypropyl-β-cyclodextrin
(HPβCD), has been shown to solubilize cholesterol and have minimal cytotoxic effects
on human cells (Szente et al. 2018). Indeed, HPβCD was studied in clinical trials for the
treatment of Niemann-Pick C, a fatal hereditary disease that can be characterized by the
buildup of cholesterol in lysosomes (Singhal et al. 2018). Theoretically, HPβCD
promotes the removal of cholesterol from these lysosomes in a similar way to
atherosclerotic plaque regression. HPβCD is a frontrunner in atherosclerosis research
because of its success in Niemann-Pick C clinical trials (Singhal et al. 2018). Another
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commonly studied cyclodextrin for atherosclerosis treatment is α-cyclodextrin (αCD).
αCD was found to inhibit inflammatory pathways better than HPβCD (Pilely et al. 2019).
In one study, αCD was also found to decrease obesity by improving lipid metabolism in
mice (Nihei et al. 2018).
A study with human erythrocytes and a Caco-2 cell line showed that αCD was
cytotoxic to these cells; however, once a complex was formed with cholesterol the
cytotoxicity of αCD decreased. This same study proposed that αCD could also form
complexes with phospholipids (Roka et al. 2015). The mechanism for cyclodextrin
cytotoxicity has not been confirmed but is speculated to be related to the removal of
cholesterol from membranes. However, the direct effect of cyclodextrins on the
cytotoxicity of gut bacteria has not been assessed.
The microbiome has become the focus of research for a variety of diseases
because of its connectivity to human health. Atherosclerosis is no exception; distinct
changes in the human gut microbiome have been noted in patients with atherosclerosis
(Jie et al. 2017). Interestingly changes in gut microbiomes of mice with atherosclerosis
has also been studied. These mice were fed high fat diets (HFD) which affected their gut
microbiome; then other mice were fed the same diet with αCD and had another large
change in bacterial composition. There was a decrease in the Bacteroides genus in mice
fed a HFD but they rebounded in mice that were treated with αCD along with their HFD.
On the other hand, Clostridium cluster XIVa was increased in mice that were fed a HFD
but drastically decreased when αCD was added (Nihei et al. 2018). These results indicate
that αCD and cholesterol are impacting the growth of the gut microbiome. Cyclodextrins
are not absorbed and are fermented by the gut bacteria, as evidenced by their absence in
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fecal analysis suggesting direct contact between the bacteria and these molecules (Amar
et al. 2016). Analysis of these changes of bacteria found that inflammation increased
when certain strains of bacteria were decreased in vivo (Yoshida et al. 2018). Clostridium
bolteae and Bacteroides vulgatus are anaerobic bacteria found in the human gut
microbiome (Maier et al. 2018). Each has their own unique properties and benefits for
overall health. B. vulgatus was studied specifically in mice with induced atherosclerosis
and was found to have anti-inflammatory effects (Yoshida, Naofumi Emoto, Takuo
Yamashita 2018). This is an important piece of information because the genus,
Bacteroides, was found to be less prevalent in the gut of mice that were fed a high fat
diet. On the other hand, C. bolteae is a member of Clostridium cluster XIVa which was
found to be increased in mice that were being fed a high fat diet (Nihei et al. 2018).
Clostridium bacteria have been found to both be proinflammatory and to help regulate
inflammation depending on the species (Barnes and Powrie 2011). A healthy balance of
gut bacteria is key to a healthy host. It is vitally important to be aware of how different
treatments affect microbiome health and to ensure that they are as beneficial as possible
and do not have unforeseen side effects. It is important to see if these bacteria are being
negatively affected by cyclodextrin treatment. The human microbiome plays an important
role in atherosclerosis so the health of these bacteria is vital and should be considered
when testing possible treatments.
Despite the promising data suggesting that cyclodextrins may help to regress
atherosclerotic plaques, the specific, direct effects of cyclodextrins on the gut bacteria B.
vulgatus and C. bolteae are not clear. In vivo studies are plagued by complex variables
that are difficult to control. Isolating individual bacteria for testing can negate these
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variables. B. vulgatus was decreased in both human and mouse studies when under
atherosclerotic conditions, while C. bolteae was decreased when αCD was introduced
into the diet of the mice. This leads to the central questions being addressed in this
current proposal: what are the effects of cyclodextrins and cholesterol on these bacterial
species? Based on the changes that occur in vivo the following hypotheses were
developed:
1. Bacteroides vulgatus will have decreased growth when grown in broth with
cholesterol. 2. Clostridium bolteae will have decreased growth when grown in broth with
cyclodextrins.
METHODS
Materials
Bacteria were purchased from ATCC, Clostridium bolteae and Bacteroides vulgatus.
Cyclodextrins were purchased from Fischer Scientific, αCD 98% (100g) and HPβCD
(100g). 92.5% cholesterol was purchased from Sigma Aldrich. Gifu Anerobic Broth was
purchased from Thomas Scientific. Olivet Nazarene University provided 12mL Falcon
tubes and 1mL, 5mL, and 10mL sterile single use pipets.
Equipment
All equipment was provided by Olivet Nazarene University: UV/VIS spectrophotometer,
shaking water bath incubator and a carbon dioxide gas tank.
Methods
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Bacteroides vulgatus was revived from frozen stock in Gifu Anaerobic Broth
(GAM) in a shaking water incubator. Growth curves were determined using the same
procedure for each trial: two bacterial falcon tubes were made containing 10 mL of fresh
broth and 0.5 mL of bacteria containing broth. These tubes were made anaerobic by
filling them with carbon dioxide gas then immediately sealing them. 1 mL samples were
taken every hour for 12 hours, alternating between two tubes. Every time a tube was
opened it was filled with carbon dioxide again. The absorbance of these samples was
immediately measured at 560 nm using the UV/Vis spectrophotometer. The absorbance
and time of each sample were recorded to create the growth curve. Samples were tested at
these times: 1hr, 2hr, 3hr, 4hr, 5hr, 6hr, 8hr, 10hr. This was found to accurately capture
the growth curve of B. vulgatus and was used for the experimental trials as well. αCD,
HPβCD, and cholesterol were all tested individually at three different concentrations:
1mM, 10mM, and 100mM. Three trials were run for each treatment to limit random error.
Clostridium bolteae was rehydrated from a freeze-dried stock in GAM broth in a
shaking water bath then frozen stocks were made as previously stated. All methods were
the same for C. bolteae apart from the times that samples were taken. The absorbances
were recorded at these times: 0.5hr, 1hr, 2hr, 2.5hr, 3hr, 4hr, 5hr, 6hr.
Growth curves were analyzed by measuring the slope of the log phase growth
where the linear upward slope was found. The slopes of each trial were compared to the
slopes of the control with a two-tailed t-test. The data is displayed as means +/- standard
deviation and P values of less than 0.05 will be used as the threshold for determining
statistical significance. While more rigorous statistical analysis is needed to more
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accurately understand the data, this was the method developed within the limited
timespan.
RESULTS
Bacteroides vulgatus has a standard sigmoidal growth curve with a linear growth
period. αCD treatments for Bacteroides vulgatus growth was not affected by αCD at
lower concentrations. However, Bacteroides vulgatus growth was completely inhibited
by 100 mM αCD (Figure 1, graphs A and B).
A.

B.
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Figure 1. 100mM alpha cyclodextrin (αCD) inhibits Bacteroides vulgatus growth. The data displayed
were from mean values with error bars showing 1 standard deviation. Graph A depicts full growth curve for
Bacteroides vulgatus under all three treatments of αCD along with a control curve. Graph B depicts
cropped graphs to display the linear growth segment that was analyzed. These two graphs display the same
set of data. Bacteroides vulgatus was grown in GAM broth under anaerobic conditions with appropriate
treatment mixed into broth. The line of best fit was found for this segment. These slopes were compared
using a two-tailed t-test..

Bacteroides vulgatus cultured with 1 mM and 10 mM cholesterol exhibited a
significant increase in growth rate. 100 mM concentrations of cholesterol and αCD
completely inhibited growth (Figure 2). These three treatments along with the 100 mM
αCD are all the statistically significant treatments for Bacteroides vulgatus. Growth
curves for HPβCD treatments are not depicted due to their lack of significant growth
inhibition.
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Figure 2.

All the cholesterol treatments for Bacteroides vulgatus affect growth. Bacteroides vulgatus

was grown in GAM broth under anaerobic conditions with appropriate treatment mixed into broth. All
three treatments were statistically significant. t-tests were run to compare the slopes. Statistical significance
was defined as P < 0.05.

All HPβCD and all cholesterol treatments along with 1 mM and 100 mM αCD
were shown to inhibit Clostridium bolteae growth (Figure 3, graphs A and B).
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A.

B.

Figure 3. 8 out of 9 treatments inhibit Clostridium bolteae growth. Graph A depicts cyclodextrin
treatments that inhibited Clostridium bolteae growth. Graph B depicts all cholesterol treatments that
inhibited Clostridium bolteae growth. Clostridium bolteae was grown in GAM broth under anaerobic
conditions with appropriate treatment mixed into broth. t-tests were run to compare the slopes of the log
phase and significance was defined as P < 0.05. All the concentrations shown were inhibiting growth.

10

Table 1 includes all the mean slope values with one standard deviation along with
their corresponding p values. P < 0.05 indicates statistical significance. There are twelve
statistically significant treatments between both bacteria tested. 1mM, 10mM and 100mM
concentrations of cholesterol and HPβCD showed statistically significant changes in
growth for Clostridium bolteae. 1mM and 100mM concentrations of αCD also show p
values of less than 0.05 for Clostridium bolteae. Bacteroides vulgatus showed
statistically significant changes in growth for 100mM αCD and 1mM, 10mM and 100mM
concentrations of cholesterol.
Table 1. 12 statistically significant changes in growth for Bacteroides vulgatus and Clostridium
bolteae. This table displays results from Bacteroides vulgatus and Clostridium bolteae under varying
conditions. Bacteria were grown in GAM broth under anaerobic conditions with appropriate treatment
mixed into broth. Slopes from the log phase of graphs for each treatment were analyzed by a two- tailed ttest, p values are shown below. There were varied levels of significance, values with p≤0.05 are marked
with *, p≤0.01 is marked with **, and p≤0.001***.
Bacteroides vulgatus
Treatment

Concentration

Slope ± 1SD

1mM

T.TEST p value

Slope ± 1SD

0.00353 ± 0.00029

0.6433

0.00403 ± 0.00058

0.02973*

10mM

0.00367 ± 0.000058

0.2746

0.0052 ± 0.00035

1

100mM

-0.000053 ± 0.000021

0.00007785***

-0.000087 ± 0.000058

0.000001363***

1mM

0.0034 ± 0.0001

1

0.00423 ± 0.0004

0.0206*

Control
Alpha Cyclodextrin

Beta Cyclodextrin

Clostridium bolteae

0.0034 ± 0.00036

T.TEST p value

0.0052 ± 0.0002

10mM

0.00357 ± 0.000058

0.4734

0.00413 ± 0.00042

0.01613*

100mM

0.00303 ± 0.000058

0.157

0.00357 ± 0.00071

0.01849*

1mM

0.00603 ± 0.00015

0.000311***

0.00463 ± 0.00012

0.01316*

10mM

0.0048 ± 0.00066

0.03166*

0.00353 ± 0.00029

0.001194**

100mM

-0.00022 ± 0.000144

0.00008642***

-0.00005 ± 0.00001

0.000001407***

Cholesterol
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DISCUSSION
This study sought to test two hypotheses: Bacteroides vulgatus will have
decreased growth when grown in broth with cholesterol and Clostridium bolteae will
have decreased growth when grown in broth with cyclodextrins. Bacteroides vulgatus
was treated with nine different treatments. Of those nine treatments, four were
statistically significant (Table 1). 2-hydroxypropyl-β-cyclodextrin (HPβCD) is
specifically designed to be less toxic; the added hydroxypropyl groups decrease the
affinity for cholesterol which has been shown to lower the toxicity (Szente et al. 2018).
The data for Bacteroides vulgatus is consistent with this purpose, even at 100 mM
HPβCD the growth of this bacteria was not significantly inhibited. The toxic effects of
unsubstituted αCD can be seen in the treatment when Bacteroides vulgatus was treated
with 100 mM αCD, it was completely inhibited. However, this inhibition is not present at
lower concentrations suggesting a tipping point of cholesterol regulation for this species.
This is consistent with the previous study that α-cyclodextrin is slightly more toxic than
2-hydroxypropyl-β-cyclodextrin but both are still being studied as treatments for
atherosclerosis (Szente et al. 2018).
The hypothesis for Bacteroides vulgatus was that it would be inhibited when
grown in broths with cholesterol. This was based on a study by Jie et al. (2017) on
patients with atherosclerosis where their gut microbiome was analyzed for consistent
changes occurring in most atherosclerotic patients. The Bacteroides genus was decreased
in general, and it was suspected that these bacteria grow poorly under high fat conditions
that are usually associated with atherosclerosis. This was supported by the study done by
Nihei et al. on mice. Cholesterol was tested because of the limited ability to replicate a
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high fat diet in vitro. This hypothesis is supported at 100 mM cholesterol concentrations
where Bacteroides vulgatus was significantly inhibited. Surprisingly, 1 mM and 10 mM
concentrations of cholesterol significantly increased the growth of Bacteroides vulgatus.
There was more increased growth in the 1 mM than the 10 mM then at 100 mM the
growth becomes inhibited. The mechanism for this increased growth in unknown. The
data presented for the lower concentrations of cholesterol contradict the predicted trend.
This may be due to the fact that the studies were using high fat diets while this study
looked at cholesterol alone (Jie et al. 2017; Nihei et al. 2018). There is more research to
be done to see where the concentrations of cholesterol transition from beneficial to
harmful. There is also a need for this study to be replicated to see if similar results are
being found. This is only one species in the Bacteroides genus and it would be beneficial
to learn if the entire genus reacts similarly to these conditions. It is difficult to draw large
conclusions based off a study on a specific bacteria, when the gut microbiome is a diverse
population. The diversity of the microbiome is key to its function and a possible
unwanted side effect of cyclodextrins could be the destruction of that diversity.
Clostridium bolteae was treated with the same nine treatments as Bacteroides
vulgatus. This bacteria was more susceptible to inhibition; it was significantly inhibited
by eight of the nine treatments. Interestingly, the only treatment that did not show any
significant changes in growth was 10 mM αCD. All other data was consistent with
previous studies. Similar to Bacteroides vulgatus, 100 mM concentrations of cholesterol
and αCD are inhibiting growth significantly. The slopes are nearly zero for these two
treatments as it is seen in table 1. The lower the concentrations, the less significant the
growth inhibition. It is interesting that 100 mM αCD has a slope of nearly zero while 100
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mM HPβCD still shows growth. This is consistent with the idea presented earlier that
HPβCD is less toxic than αCD (Szente et al. 2018).
The hypothesis for Clostridium bolteae was that there would be inhibited growth
when grown in broth with cyclodextrins. This is supported by results from a study on
mice that were treated with cyclodextrins, and they had decreased Clostridium
populations (Nihei et al. 2018). In general, this is supported with the data from this study,
except for 10 mM αCD. It is key to note that Bacteroides vulgatus was unaffected by
HPβCD but Clostridium bolteae had significant growth inhibition at all concentrations.
This supports that hypothesis that Clostridium bolteae is specifically inhibited by
cyclodextrins even the one deemed less toxic. Clostridium bolteae also showed
significant growth inhibition for cholesterol at all concentrations. In Jie’s study on
atherosclerotic patients the Clostridium genus was increased in these patients, unlike the
Bacteroides genus. There is not research supporting the decreased growth of Clostridium
bolteae in cholesterol. Bacteroides vulgatus is not entirely representative of the
Bacteroides genus and the Clostridium genus is even more varied (Barnes and Powrie
2011). There is a need for further research on other members of the Clostridium genus to
explain the increase of the population under atherosclerotic conditions. There is a
possibility that Clostridium bolteae decreases but other species thrive. This possibility
points to the importance of expanding the study to include a large variety of species of
gut bacteria.
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CONCLUSION
The results from these two gut bacteria species show that cyclodextrins can inhibit
growth of gut bacteria, although further research should be done to see if this inhibition
will be universally detrimental to the gut microbiome. The results indicate that there is
some dose dependence for the inhibition. Further statistical analysis with a more rigorous
method should be used to gain clearer picture of the data. The health of gut microbiome
composition should be monitored in future clinical research. Further research is needed to
fully understand the general impact that cyclodextrins would have on the gut
microbiome. This study was limited by the small number of bacteria tested along with
limited concentration range. The maintenance of an anerobic environment was difficult to
control and while every attempt was made to control the environment, oxygen
contamination could contribute to the results. Overall, this research supports
cyclodextrins having adverse side effects on gut bacteria while raising new questions for
future work.
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